文献速递卫生政策与健康促进免疫规划

将卫生经济学评价纳入加拿大免疫规划决策:障碍与促进因素

Incorporation of health economic evaluation into immunization policy-making in Canada: Barriers and facilitators.
PubMed 文献 · Vaccine · 2020-02-11

本研究采用混合方法,对加拿大联邦、省、地区公共卫生关键知情者及国家免疫研究网络成员进行横断面调查和半结构化访谈,探讨将经济学评价用于免疫规划决策的障碍与促进因素。调查参与者中70%指出人力和财力资源有限,39%报告缺乏解读经济学证据的专业能力;受访者认为疫苗效果和疾病负担比成本效果更重要。促进因素包括在国家层面开展评价或通过省际协作共享评价工作。

要点

  • 70%的调查受访者指出开展经济学评价的人力和财力资源有限。
  • 39%的调查受访者报告缺乏解读经济学证据的专业能力。
  • 受访者认为疫苗效果和疾病负担比成本效果更重要。

核心结论

  • 所有受访者支持增加经济学评价的使用并使其成为免疫规划决策的常规部分。
  • 将经济学评价纳入加拿大免疫规划决策的障碍包括缺乏开展评价的人力和财力资源以及对经济学证据的理解。
  • 国家、省和地区公共卫生行为者报告,促进因素包括发展开展和使用经济学评价的更大能力,以及建立跨辖区系统来共享经济学评价工作或通过国家领导。

研究设计与样本

  • 混合方法研究,包括横断面调查和半结构化访谈。
  • 调查对象为加拿大国家、省和地区公共卫生层面关键知情者及国家免疫研究网络成员。
  • 63名调查参与者中,12名为联邦、省或地区关键知情者(应答率12/31,39%),51名为研究网络成员(应答率51/214,24%)。
  • 11名利益相关者提供了半结构化访谈。

主要发现

  • 70%的调查受访者指出开展经济学评价的人力和财力资源有限。
  • 39%的调查受访者报告缺乏解读经济学证据的专业能力。
  • 调查受访者和访谈者认为疫苗效果和疾病负担比成本效果更重要。

临床怎么用

  • 所有受访者支持增加经济学评价的使用并使其成为免疫规划决策的常规部分。
  • 调查受访者和访谈者认为疫苗效果和疾病负担比成本效果更重要。
  • 潜在促进因素为经济学评价在国家层面开展,或通过省和地区间协作以协调但分散的方式开展评价。
  • 国家、省和地区公共卫生行为者报告,促进因素包括发展开展和使用经济学评价的更大能力,以及建立跨辖区系统来共享经济学评价工作或通过国家领导。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Despite the WHO recommendation that economic evidence be considered in national vaccine recommendations, this element of decision-making has been lacking or not done routinely in Canada. This study aimed to investigate barriers and facilitators to using economic evaluations in public health immunization programs decision-making across Canadian jurisdictions. METHODS: This mixed methods study consisted of a cross-sectional survey and semi-structured interviews of national, provincial and territorial public health level key informants, and of members of the national immunization research network in Canada. Barriers were categorized according to accessibility (e.g. access to human resources to conduct the evaluation) and acceptability (e.g. political resistance to using the evaluation). RESULTS: Of 63 survey participants, 12 were federal, provincial or territorial key informants (response rate 12/31, 39%) and 51 were members from the research network (response rate 51/214, 24%). Eleven stakeholders gave semi-structured interviews. All respondents support increased use of economic evaluation and of it becoming a routine part of immunization policy-making. However, 70% of the survey respondents identified limited resources (human and financial) to perform economic evaluations, and 39% reported lack of expertise to interpret economic evidence. Vaccine effectiveness and the burden of disease were seen as more important than cost-effectiveness by survey respondents and interviewees. Potential facilitators were for economic evaluations to either be conducted at the national level, or through a collaboration between provinces and territories with capacity to address shared needs so that evaluations occurred in a co-ordinated but distributed way. RECOMMENDATIONS: Barriers to incorporation of economic evaluation in immunization policy-making in Canada include lacking human and financial resources to conduct them and understanding of economic evidence. National, provincial and territorial public health actors reported that facilitators to incorporating economic evidence include developing increased capacity to conduct and use economic evaluations and establishing inter-jurisdictional systems to share the work of conducting economic evaluation and/or by national leadership.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Hopman HA, Crowcroft NS, Cesuroglu T, et al. Incorporation of health economic evaluation into immunization policy-making in Canada: Barriers and facilitators. Vaccine. 2020. PMID: 32057578. doi:10.1016/j.vaccine.2020.01.092

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。